Identifying epidermal growth factor receptor mutation status in patients with lung adenocarcinoma by three-dimensional convolutional neural networks.
暂无分享,去创建一个
Jie Zhang | Wen Yu | Xuwei Cai | X. Fu | Xiaoyang Li | Zhiyong Xu | Jun Zhao | Xiao-Long Fu | L. Fu | Xu-Wei Cai | Ling Fu | Jun-Feng Xiong | Tian-Ying Jia | Xiao-Yang Li | Zhi-Yong Xu | Bin-Jie Qin | Jun Zhao | Wen Yu | Jie Zhang | Tian-Ying Jia | Junfeng Xiong | Binbin Qin
[1] P. Lambin,et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.
[2] Y. Liu,et al. Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas. , 2016, Clinical lung cancer.
[3] Hao Chen,et al. Multilevel Contextual 3-D CNNs for False Positive Reduction in Pulmonary Nodule Detection , 2017, IEEE Transactions on Biomedical Engineering.
[4] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[5] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[6] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[7] P. Jänne,et al. Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses , 2015, Clinical Cancer Research.
[8] Zijuan Zhao,et al. MLW-gcForest: a multi-weighted gcForest model towards the staging of lung adenocarcinoma based on multi-modal genetic data , 2019, BMC Bioinformatics.
[9] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Sebastian Thrun,et al. Dermatologist-level classification of skin cancer with deep neural networks , 2017, Nature.
[11] Paul Kinahan,et al. Radiomics: Images Are More than Pictures, They Are Data , 2015, Radiology.
[12] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[13] Mehmet Toner,et al. Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.
[14] Zhi Zheng,et al. Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood , 2013, Analytical and Bioanalytical Chemistry.
[15] W. Tsai,et al. Reproducibility of radiomics for deciphering tumor phenotype with imaging , 2016, Scientific Reports.
[16] R. Gillies,et al. MO-DE-207B-08: Radiomic CT Features Complement Semantic Annotations to Predict EGFR Mutations in Lung Adenocarcinomas. , 2016, Medical physics.
[17] Xiang Hu,et al. Predictive models for patients with lung carcinomas to identify EGFR mutation status via an artificial neural network based on multiple clinical information , 2019, Journal of Cancer Research and Clinical Oncology.
[18] Yi Liu,et al. Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer. , 2015, The Journal of molecular diagnostics : JMD.
[19] Y. Yatabe,et al. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer , 2007, Cancer science.